Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) FCF Margin (2022 - 2025)

BioXcel Therapeutics has reported FCF Margin over the past 4 years, most recently at 5550.78% for Q4 2025.

  • Quarterly results put FCF Margin at 5550.78% for Q4 2025, down 150461.0% from a year ago — trailing twelve months through Dec 2025 was 8974.3% (down 579570.0% YoY), and the annual figure for FY2025 was 8974.3%, down 579570.0%.
  • FCF Margin for Q4 2025 was 5550.78% at BioXcel Therapeutics, up from 19170.41% in the prior quarter.
  • Over the last five years, FCF Margin for BTAI hit a ceiling of 464757.14% in Q1 2022 and a floor of 25414.08% in Q1 2023.
  • Median FCF Margin over the past 4 years was 7401.52% (2025), compared with a mean of 19794.74%.
  • Biggest five-year swings in FCF Margin: tumbled -49017122bps in 2023 and later skyrocketed 2237181bps in 2024.
  • BioXcel Therapeutics' FCF Margin stood at 16234.87% in 2022, then surged by 56bps to 7144.41% in 2023, then surged by 43bps to 4046.17% in 2024, then tumbled by -37bps to 5550.78% in 2025.
  • The last three reported values for FCF Margin were 5550.78% (Q4 2025), 19170.41% (Q3 2025), and 10479.17% (Q2 2025) per Business Quant data.